Repligen Corporation $RGEN Stake Cut by Vanguard Group Inc.

by · The Markets Daily

Vanguard Group Inc. lessened its holdings in Repligen Corporation (NASDAQ:RGEN – Free Report) by 0.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,044,191 shares of the biotechnology company’s stock after selling 32,981 shares during the quarter. Vanguard Group Inc. owned approximately 8.97% of Repligen worth $674,257,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Hantz Financial Services Inc. boosted its holdings in shares of Repligen by 2,663.6% in the 2nd quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 293 shares during the period. CWM LLC lifted its holdings in Repligen by 67.2% in the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 135 shares during the last quarter. Center for Financial Planning Inc. boosted its stake in Repligen by 34.2% in the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 126 shares during the period. Trust Co. of Vermont acquired a new position in Repligen in the third quarter valued at approximately $67,000. Finally, Wilmington Savings Fund Society FSB grew its holdings in shares of Repligen by 2,750.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 495 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Repligen

In related news, Director Karen A. Dawes sold 275 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the transaction, the director owned 91,821 shares of the company’s stock, valued at $14,783,181. This trade represents a 0.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.20% of the stock is currently owned by company insiders.

Repligen Trading Down 0.2%

Shares of NASDAQ:RGEN opened at $135.40 on Tuesday. The company has a 50 day moving average of $156.30 and a 200-day moving average of $146.71. The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26. The firm has a market cap of $7.62 billion, a P/E ratio of 6,773.39, a P/E/G ratio of 2.48 and a beta of 1.13. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $175.77.

Repligen (NASDAQ:RGEN – Get Free Report) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. The firm had revenue of $197.91 million for the quarter, compared to analysts’ expectations of $192.23 million. Repligen had a return on equity of 4.66% and a net margin of 0.25%. As a group, analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on RGEN shares. Wall Street Zen upgraded Repligen from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. Wells Fargo & Company raised their target price on Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Barclays boosted their price target on shares of Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Canaccord Genuity Group increased their price objective on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a report on Wednesday, October 29th. Finally, UBS Group boosted their target price on shares of Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and a consensus price target of $177.92.

Read Our Latest Stock Report on RGEN

Repligen Profile

(Free Report)

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

Further Reading

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).